Autolus Therapeutics Ltd (AUTL)vsModerna Inc (MRNA)
AUTL
Autolus Therapeutics Ltd
$1.88
-4.08%
HEALTHCARE · Cap: $500.39M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 206483% more annual revenue ($2.23B vs $1.08M). AUTL leads profitability with a 0.0% profit margin vs -141.4%. AUTL earns a higher WallStSmart Score of 29/100 (F).
AUTL
Avoid29
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+55.5%
Fair Value
$3.21
Current Price
$1.88
$1.33 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 83655.0% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AUTL
The strongest argument for AUTL centers on Price/Book, Revenue Growth. Revenue growth of 83655.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : AUTL
The primary concerns for AUTL are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AUTL profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
AUTL carries more volatility with a beta of 2.00 — expect wider price swings.
AUTL is growing revenue faster at 83655.0% — sustainability is the question.
AUTL generates stronger free cash flow (-26M), providing more financial flexibility.
Bottom Line
AUTL scores higher overall (29/100 vs 21/100) and 83655.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Autolus Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?